From the 35th Annual Meeting - Las Vegas, Nevada- November 2006
The file you requested will begin playing automatically. If it does not, press the 'play' button. If you experience playback problems, make certain you have the latest version of Windows Media Player, available here. If you have the latest Windows Media Player and still experience problems, email the OBGYN.net Webmaster with a description of the problem and any error messages you may have received.
FDA grants IND clearance to DARE-VVA1 for dyspareunia
December 7th 2023Daré Bioscience's tamoxifen-based therapy, DARE-VVA1, secures FDA clearance for an investigational new drug application, offering hope for women with contraindications to estrogen therapies suffering from the underdiagnosed condition of vulvar and vaginal atrophy.
Read More
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More